SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The dominant conversation centers on MELANIAs steep post-launch collapse and allegations that it is a Trump-family pump-and-dump scheme with little utility, prompting widespread criticism from holders and traders. A small minority still promotes dip-buying, a rebound, or a short squeeze, but bearish skepticism clearly dominates.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Larger-than-average natural-gas storage builds, elevated production, and cooling weather forecasts are driving bearish sentiment around BOIL, with Freeport LNG maintenance limiting export demand. Traders remain divided between expectations of further weakness and a potential heat-driven short squeeze, while many warn that contango, roll costs, and leveraged decay amplify downside risk.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios completion of the first German labeling and packaging run for ANKTIVA is driving discussion about the drugs European commercial rollout and potential revenue expansion. Traders are also speculating about future UAE and Saudi approvals for broader uses such as lymphopenia, while skeptics note that those developments lack formal confirmation and point to continued short- and options-related volatility.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A bearish BMF short report questioning SELLASs REGAL Phase 3 trial design, survival assumptions, dilution and valuation triggered the selloff, despite no reported adverse clinical update. Traders are divided between viewing the report as a self-interested short thesis and focusing on the pending 80th-event announcement and REGAL topline data as the decisive catalysts.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

A strong second-quarter earnings report, raised outlook, and expanded Anthropic partnership through Claudeforce have fueled a sharp Salesforce rally and renewed optimism that AI can monetizeand augment rather than replaceenterprise software. Bulls view the move as a break from the SaaSpocalypse narrative, while skeptics argue the reaction is overextended and that buybacks, acquisitions, and still-muted organic growth weaken the case for sustained gains.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura is drawing attention after CEO Troy Wilson disclosed another open-market purchase of 100,000 shares, which traders view as a strong confidence signal and a potential catalyst for short covering. Discussion also highlights improving KOMZIFTI launch traction and upcoming frontline AML and darlifarnib data, though some investors remain cautious about valuation, cash burn, and the stocks recent weakness.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

UNDPs collaboration with DFINITY to explore sovereign cloud and AI infrastructureincluding pilots in several countries and Pakistan-related developmentis driving attention around ICP. Traders view the initiatives as potential institutional adoption, while skeptics note they remain pilots without confirmed revenue or broad usage and question ICPs tokenomics and weak price performance.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canada is drawing attention after monetizing a minority stake in Aeroplan and posting better-than-expected quarterly results, with proceeds supporting debt repayment and share buybacks. Traders are largely bullish on the valuation unlock, strong travel demand and potential short covering, while skeptics remain focused on fuel costs, labor expenses and leverage.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Updated HARMONi Phase 3 overall-survival data for ivonescimab, showing a more consistent benefit across Western and Asian patients, has renewed attention ahead of the FDAs November decision. Traders remain divided over whether the survival results satisfy the FDAs statistical requirements, while concerns about dilution and funding needs weigh on sentiment.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Anticipation of Intellia completing its rolling BLA and receiving FDA acceptance for lonvo-z, following positive Phase 3 HAELO results, is the main catalyst. Bullish traders focus on potential commercialization and heavy short interest, while skeptics cite dilution, cash burn, commercialization hurdles, and a recent analyst downgrade as risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
